This protein-protein interactions network was constructed by mapping potential targets in food allergy, IgE, and mast cell diseases to the Strings database. The size of the node from large to small is proportional to its degree value in the network. The circles represent the therapeutic targets, and the purple lines represent the interaction between the nodes. Credit: Ibrahim Musa, New York Medical College
Study uncovers new drug targets for treating other allergic disorders.
Researchers combined advanced computational methods with experimental studies to gain new insight, at the cell level, into how the plant compound formononetin might be used to treat food allergies. With nearly 10% of the world population affected by food allergies — which are sometimes life-threatening — new treatments are critically needed.
Formononetin is found in plants and herbs such as red clover and green beans and has been shown to have anticancer properties. It is a phytoestrogen, meaning that it has a structure similar to the hormone estrogen and can bind to the body’s estrogen receptors.
“Our findings show that formononetin is a particularly good therapeutic candidate for treating food allergies,” said Ibrahim Musa, a doctoral candidate in pathology, microbiology and immunology at New York Medical College. “Our research also revealed new mechanisms and targets that can be utilized to design future drugs for treating food allergies and other allergic disorders or to prevent severe anaphylaxis seen in allergic diseases.”
Musa presented the new research at the American Society for Biochemistry and Molecular Biology annual meeting during the Experimental Biology (EB) 2022 meeting, which was held on April 2-5, 2022, in Philadelphia.
Food allergies occur when the immune system treats a food or something in a food as a threat. This causes the immune system to produce immunoglobulin E (IgE) antibodies that react to the food and can cause allergy symptoms such as hives, asthma, itching, trouble breathing or diarrhea.
In previous studies, the researchers identified formononetin as a potential therapeutic for allergies because it decreased IgE production. To find out more, the researchers turned to an approach known as systems pharmacology. This involved using data from publicly available databases to identify gene and protein targets regulated in food allergy and mast cells diseases. Mast cells also play an important role in IgE-mediated allergic diseases.
Once they identified gene and protein targets, the researchers validated them using cultured cell lines that are commonly used in allergy studies. These cell experiments showed that formononetin did influence the expression of gene and protein targets identified using systems pharmacology.
“Our study demonstrates that system pharmacology can be used to predict drug/ compound–target interaction,” said Musa. “What’s more, the mechanism of action identified for formononetin is also important for other allergic diseases such as allergic asthma and hay fever. This suggests that formononetin or other therapeutic candidates that decrease IgE production could be useful for treating these diseases.”
The researchers have developed a mouse model of peanut allergy that they plan to use to study formononetin and identify potential side effects.
Ibrahim Musa will present this research from 12:30–1:45 p.m. Tuesday, April 5, in Exhibit/Poster Hall A-B, Pennsylvania Convention Center (Poster Board Number A235) (abstract). This work will be featured in a virtual press conference from 11–11:45 a.m. EDT on Friday, April 1 (RSVP by Thursday, March 31). Contact the media team for more information or to obtain a free press pass to attend the meeting.
Meeting: Experimental Biology 2022
Source: SciTechDaily
